New analysis: Psychedelics may be no better than SSRIs in treating depression, Kentucky ibogaine bill and New Mexico psilocybin equity fund
Plus: Bretisilocin becomes first psychedelic to receive EU priority medicines, Psychedelic Medicine Association's accreditation program and Oregon palliative psilocybin lawsuit inching forward
External link. We are not responsible for the content.
Read more ↗More From The Microdose (Berkeley)
The poster child for psychedelic mushrooms is named after a country that doesn’t use it
On the history of Psilocybe cubensis and Cuba
An Amanita mushroom poisoning outbreak in California; A case report testing psilocybin for advanced Alzheimer’s disease
Plus: Scientists assess risk of psychedelic-induced mania; and the close of this season’s psychedelic legislation push
Dispatch from The Netherlands Part 2
Reporting from the Interdisciplinary Conference on Psychedelic Research
Latest News
MAPS Statement on the Supreme Court’s Ruling in United States v. Hemani
June 18, 2026 — In United States v. Hemani, the U.S. Supreme Court ruled today that the federal government’s prosecut...
Psychedelic Policy Briefing: Week of June 16, 2026
Federal psychedelic policy in 2026 splits in two directions. Lawmakers and military officials are building clinical i...
Here’s How to Make a Psilocybin Mushroom Tincture At Home
Gatekeeping isn't cool. Here's how to safely make a trippy mushroom tincture from the comfort of your home. [...] Rea...
New Series Asks Maestros About Ayahuasca’s Globalization
PLUS Psychedelics and sports, late-stage capitalism, and coming out of the drug use closet. [...] Read More... The po...
The Psychedelic Retreat Bubble
This week’s Sunday Insider: Psychedelic retreats are booming.
Out of This World: Why AI Belongs Beside the Therapist
Safar founder Sabba Nazhand watched the mental health system fail his mother, then himself. He argues AI's place is b...